Abstract: What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a mixture of a triglyceride of ricinoleic acid and a gelling agent, in a formulation with loteprednol, latanoprost, celecoxib, triamcinolone, or betamethasone and, optionally, a second corticosteroid, analgesic, or anti-inflammatory agent.

Abstract: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.

Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Abstract: What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a mixture of a triglyceride of ricinoleic acid and a gelling agent, in a formulation with loteprednol, latanoprost, celecoxib, triamcinolone, or betamethasone and, optionally, a second corticosteroid, analgesic, or anti-inflammatory agent.

Abstract: What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a triglyceride of ricinoleic acid, a gelling agent, bupivacaine and, optionally, a corticosteroid, an analgesic, or an anti-inflammatory agent.

Abstract: What is disclosed is a semi-solid controlled release pharmaceutical composition containing biocompatible and bioerodible semi-solid lipid matrix incorporating local anesthetics agents to form a semi-solid solution, a method of using the pharmaceutical composition to treat, and a method of making the pharmaceutical composition.

Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Abstract: What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a triglyceride of ricinoleic acid, a gelling agent, bupivacaine and, optionally, a corticosteroid, an analgesic, or an anti-inflammatory agent.

Abstract: The invention relates to an implementation method of a non-radix-2-point multi data mode FFT. The implementation method comprising: using the mixed radix algorithm and prime factor decomposition algorithm to decompose the original FFT operation as the cascaded FFT operations of the multi-level programmable WFTA operations. The first-level programmable WFTA unit implements 3 point, 3 point, 5 point, and 3 point FFT operations. The second-level programmable WFTA unit implements 4 point, 5 point, 5 point, and 5 point FFT operations. The third-level programmable WFTA unit implements 9 point, 8 point, 5 point, and 9 point FFT operations. The fourth-level programmable WFTA unit implements 5 point, 5 point, 5 point, and 5 point FFT operations. The fifth-level programmable WFTA unit implements 7 point, 7 point, 7 point, and 7 point FFT operations. Each level of the programmable WFTA units is an FFT operation stage.

Abstract: What is described is a semi-solid controlled release composition comprising a semi-solid lipid and bupivacaine in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.

Abstract: The present invention relates to stable liquid formulations of ketoprofen, amitriptyline, and oxymetazoline.

Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Abstract: What is described is a semi-solid controlled release composition comprising a semi-solid lipid and bupivacaine in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.

Abstract: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.

Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Abstract: Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.

Abstract: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.

Abstract: What is described is a semi-solid controlled release composition comprising a semi-solid lipid pharmaceutical active agent in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.

Abstract: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.